Immunotherapies have demonstrated efficacy and survival benefits in some patients suffering from brain tumors; however, most do not respond and new approaches to enhance anti-tumor immunotherapeutic responses in the brain are needed. Radiotherapy remains a commonly used cancer treatment modality and can augment immunotherapeutic responses through multiple mechanisms. Recent preclinical studies may provide insight on how to optimally combine radiation and immunotherapies to maximize treatment efficacy. Unique aspects of the brain tumor microenvironment may play a critical role in limiting the successful application of immunotherapies in this location. Emerging studies suggest that such limits may be redressed through combination of immunotherapies with radiation therapy. In these settings, the latter may play a critical role in immunomodulating both tumor cells and the radiated brain tumor microenvironment. This review analyzes recent developments in combining radiation and immunotherapies to prime and better propagate anti-tumor immune response against brain tumors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639822 | PMC |
http://dx.doi.org/10.1007/s12017-021-08668-w | DOI Listing |
Sci Rep
January 2025
Department of Biochemistry and Molecular Biology, Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Key Laboratory of Coal Environmental Pathogenicity and Prevention (Ministry of Education, China, Shanxi Medical University, No. 56, Xinjian South Road, Yingze District, Taiyuan City, 030000, Shanxi Province, China.
There are many similarities between early embryonic development and tumorigenesis. The occurrence of neural tube defects (NTDs) and glioblastoma (GBM) are both related to the abnormal development of neuroectodermal cells. To obtain genes related to both NTDs and GBM, as well as small molecule drugs with potential clinical application value.
View Article and Find Full Text PDFNat Commun
January 2025
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Oncolytic viruses (OVs) emerge as a promising cancer immunotherapy. However, the temporal impact on tumor cells and the tumor microenvironment, and the nature of anti-tumor immunity post-therapy remain largely unclear. Here we report that CD4 T cells are required for durable tumor control in syngeneic murine models of glioblastoma multiforme after treatment with an oncolytic herpes simplex virus (oHSV) engineered to express IL-12.
View Article and Find Full Text PDFSemin Oncol Nurs
January 2025
Pelvic Floor Diseases Center, West China Tianfu Hospital, Sichuan University, Chengdu, China. Electronic address:
Objectives: To identify composition, predictors, outcomes and stability of symptom clusters in brain tumor patients and to examine assessment tools and statistical methods.
Methods: The PubMed, Web of Science, Embase, CINAHL, and Cochrane Library databases were systematically searched. Two reviewers independently screened the titles, abstracts and full texts.
No Shinkei Geka
January 2025
Department of Neurosurgery, Osaka Medical and Pharmaceutical University.
Surgery for spinal intramedullary tumors remains a major challenge for neurosurgeons. Successful surgery requires experience, skill, and intraoperative imaging support. Fluorescence imaging technology has become a valuable support in neurosurgical procedures of not only the brain but also the spinal cord.
View Article and Find Full Text PDFClin Neurol Neurosurg
January 2025
Department of Neurological Surgery, Pauline Braathen Neurological Center, Cleveland Clinic Florida, Weston, FL, USA. Electronic address:
Early prediction of recurrence in high-grade glioma (HGG) is critical due to its aggressive nature and poor prognosis. Distinguishing true recurrence from treatment-related changes, such as radionecrosis, is a major diagnostic challenge. Machine learning (ML) offers a novel approach, leveraging advanced algorithms to analyze complex imaging data with high precision.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!